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Restorative therapies aim to improve outcome and function by promoting plasticity within a 
therapeutic time window between days to weeks to years.  In this article, the mechanisms by which 
cell-based, pharmacological and robotic treatments stimulate endogenous brain remodelling after 
stroke, particularly neurogenesis, axonal plasticity and white-matter integrity are described with a brief 
outline of the potential of neuroimaging (fMRI) techniques.  Stem cells aid stroke recovery via 
mechanisms depending on the type of cells used. Transplanted embryonic stem cells (ESCs), induced 
pluripotent stem cells (iPSCs), and neural stem cells (NSCs) can replace the missing brain cells in the 
Infarcted area, while adult stem cells, such as mesenchymal stem cells or multipotent stromal cells 
(MSCs) and MNCs, provide trophic support to enhance self-repair systems such as endogenous 
neurogenesis.  Most preclinical studies of stem cell therapy for stroke have emphasized the need to 
enhance self-repair systems rather than to replace lost cells, regardless of the type of cells used.  
Noninvasive brain stimulation (NIBS) provides a valuable tool for interventional neurophysiology by 
modulating brain activity in a speciﬁc distributed, cortico-subcortical network.  The two most 
commonly used techniques for noninvasive brain stimulation are transcranial magnetic stimulation 
(TMS) and transcranial direct current stimulation (tDCS).  The article also discusses the potential role 
and current evidence for the use of pharmacological therapy, robotics and speciﬁc forms of 
physiotherapy regimes in optimizing stroke recovery.  Neurorestoration is a concept that has been 
proven emphatically in several experimental models and clinical studies of stroke.  Elucidating the 
underlying mechanisms of cell-based, pharmacological and rehabilitative therapies is of primary 
interest and crucial for translation of treatments to clinical use.  The knowledge must provide an 
impetus for the development of superior, advanced and cost effective neuro restorative interventions 
that will enhance stroke recovery.
Keywords : Cerebral stroke, stroke therapy, functional neuroimaging. 
ABSTRACT
Introduction
 Stroke is the second leading cause of 
mortality and morbidity with approximately half 
of them dependent on care givers resulting in 
s i g n i ﬁ c a n t  h e a l t h  c a r e  c o s t s  ( 1 ) .  
Neuroprotection in the form of thrombolytic 
therapy is an inherent treatment for ischemia 
with only 5.2% receiving treatment in the 
window period (2). Acute stroke interventions 
for hemorrhagic stroke are limited. After much 
research focussed on acute neuroprotection, the 
National Institute of Neurological Disease and 
Stroke (NINDS) progress review group in 2006 
and 2011 identiﬁed neurorestoration after stroke 
as a major priority for stroke research (3). 
 Restorative therapies aim to improve 
outcome and function by promoting plasticity 
within a therapeutic time window between days 
to weeks to years vis-a-vis reperfusion or 
neuroprotective drugs which act on salvageable 
brain (4).  The aforementioned armamentarium 
includes growth factors, cell-based therapies, 
drugs and devices. Pharmacological treatment 
includes drugs that increase cGMP (e.g. 
phosphodiesterase 5 inhibitors, such as sildenaﬁl 
and tadalaﬁl) ,  s ta t ins ,  erythropoiet in , 
granulocyte-colony stimulating factor and 
minocycline (5). 
 There is an unmet need to design and 
improvise newer interventions to help patients 
repair and return to normal function. In this 
article, the mechanisms by which cell-based, 
pharmacological and robotic treatments 
stimulate endogenous brain remodelling after 
stroke, particularly neurogenesis, axonal 
plasticity and white-matter integrity are 
described with a brief outline of the potential of 
neuroimaging (fMRI) techniques (6). 
Brain Insult: Repair and Recovery
 The injury and recovery mechanisms after 
stroke have been extensively studied.  The ﬁrst 
epoch is related to acute injury and takes place in 
the ﬁrst initial hours after stroke when changes in 
blood ﬂow, edema, metabolism rate and 
diaschisis occur.  A second epoch is related to 
repair, which starts days after stroke and lasts for 
several weeks and is referred to as endogenous 
repair suggesting a golden period for initiating 
restorative therapies.  A third epoch occurs 
weeks to months after stroke when spontaneous 
recovery gains have plateaued with residual 
deﬁcits which may or may not be modiﬁable (7, 
8).
Cell-based Interventions :Stem Cells 
 Stem cells can be deﬁned as clonogenic 
cells that have the capacity to self-renew and 
differentiate into multiple cell lineages. They are 
divided according to the body's development 
process and their ability to form other cells (9). 
Totipotent stem cells are capable of giving rise to 
an entire organism and can be derived from 
fertilized oocytes and cells of the developing 
zygote up to the eighth cell stage. They have the 
potential to differentiate into derivatives of all 
germ layers (ectoderm, endoderm and 
mesoderm).  Pluripotent stem cells can give rise 
to all tissue types, from any of the three 
embryonic germ layers, but unlike totipotent 
cells cannot give rise to an entire organism (10). 
These cells can give rise to different types of 
cells representing derivatives of two different 
germ layers, e.g. skin (ectoderm) and muscle 
(mesoderm). Multipotent stem cells are able to 
differentiate into multiple types of cells, but 
within one organ system (e.g. blood) (11). 
Progenitor cells differentiate into mature cells 
(e.g. endothelial progenitor cells) and can only 
divide a limited number of times, are laid 
between stem cells and fully differentiated cells 
(12-14).
 The omnipresent nature of these cells, 
their clear role in neural tissue development, 
their presumed participation in repair and 
regeneration and the irrefutable success of bone 
marrow stem cell therapy have raised high 
expectations to cure diseases that have thus far 
proven resistant to conventional therapy such as 
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stroke (15,16). The success of “bench to 
bedside” of cell transplantation in the last decade 
has seen a spurt of stem cell research in various 
pathological disorders, albeit all such clinical 
studies are/were phase 1/2 which aimed at safety 
and feasibility of cells.
Human Umbilical Cord Blood Cells (UCB)
 These cells are derived from umbilical 
cord blood with a wonderous potential of 
differentiation into neural lineages (17).  When 
exposed to nerve growth factor and retinoic acid, 
the derived umbilical cord blood cells produce 
progeny that shows positivity of neural and glial 
cells markers.  A better understanding of these 
cells is needed before clinical transplantation 
studies ensue, although experimental data in 
animal models of stroke have shown functional 
beneﬁts (18,19).  However, biology of these 
cells is poorly understood, and it is likely that 
positive effects of these cells are related to their 
neurotrophic action, rather than actual neuronal 
circuitry formation.
Immortalised Cell Lines
 These cell lines are derived by infecting 
neuroepithelial precursor cells from predeﬁned 
CNS regions before terminal mitosis, with a 
retrovirus encoding an immortalizing oncogene 
view of the ethical difﬁculties in transplanting 
embryonic cells and technical problems in 
xenotransplantation, alternative sources of graft 
cells have been devised (20).
Fetal Neural Stem Cells
 These cells maintain a normal karyotype 
for a signiﬁcant number of passages in culture 
and can produce a large number of neurons and 
astrocytes and are harvested from the post-
mortem human fetal brain.  These possess a 
relatively high proliferative capacity without 
any evidence of tumorogenesis following 
transplantation (21).
Adult Neural Stem Cells (NSC)
 Adult stem cells are multipotent stem cells 
found in developed organisms, which are used to 
replace cells that have died or lost function (22). 
NSCs are deﬁned as undifferentiated cells that 
are able to self - renew as well as generate three 
major cell types of CNS: neurons, astrocytes and 
oligodendrocytes, signifying their pluripotent 
nature (23).  They have been identiﬁed within 
many different organ systems, including bone 
marrow, brain, heart, skin and bone.  Adult stem 
cells make up 1-2% of the total cell population 
within a particular tissue type.  They are usually 
quiescent and held in an undifferentiated state 
until they receive a stimulus to differentiate (24).
Bone Marrow Derived Cells
 These have hematopoietic and non-
hematopoietic component, the former being 
abundant in bone marrow (25).  Mobilized 
Peripheral Blood (MPB) is also a clinical source 
of heme cells, containing a mixture of 
hematopoietic stem and progenitor cells 
enriched with CD34 (26,27).  These cells have 
the potential to regenerate the brain tissue by 
release of neurotrophic growth hormones.  The 
other component of bone marrow contains 
mesenchymal stem cells or multipotent stromal 
cells (MSCs) described as colony-forming units 
(CFUs) that adhere to cell culture surfaces and 
can be differentiated into osteoblasts, adipocytes 
and chondrocytes (28-30).  MSCs secrete inter 
leukin-6 (IL-6), IL-7, IL-11, IL-12, leukemia 
inhibitory factor (LIF), macrophage-colony 
stimulating factor (M-CSF), stem cell factor 
(SCF) and ﬂt-3ligand (31).
Induced Pluripotent Stem Cells (iPSCs)
 These cells are similar to human 
embryonic stem cells (ESCs) in morphology, 
proliferation, surface antigens, gene expression, 
epigenetic status of pluripotent cell-speciﬁc 
genes and telomerase activity (32).  Adult 
human cells from skin were transformed to a 
pluripotent state using genetic engineering 
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Study design 
control cell 
group
 Characteristics of 
stroke
 
Manipulation
(cell done)
 
Route Efﬁcacy Adverse effects
Autologous bone marrow mononuclear cells
 
1. None : 5 
patients 1-year 
f/u
 
Chronic Ischemic or 
ICH
 
Isolation using 
normal saline
 
IC
 
N/A
 
None
 
2. None
 
:
 
6 
patients 6-
month f/u
 
Subacute MCA infarct
 
Isolation using 
human albumin-
containing normal 
saline (0.6-5x10
2
)
 
IA
 
N/A
 
Seizure after 200 
days
 
3. None : 10 
patients 6-
month f/u
 
Acute Large MCA 
infarct
 Isolation using 
human albumin-
containing normal 
saline (0.6-5x10
2
)
 
IV
 
Limited study 
design
 None
 
4. None : 20 
patients 6-
month f/u
 
Acute Nonlacunar 
infarct
 Isolation using 
human albumin-
containing normal 
saline (0.6-5x10
2
)
 
IA
 
Limited study 
design
 None
 
5. 40 : 60 patients 
6-month f/u
 
Acute ICH
 
Isolation using 
normal saline 
(1.33x10
2
)
 
IC
 
NIHSS and BI 
improved
 
None
 
6. 60 : 60 patients  Subacute MC/ACA 
infarct 
Isolation using 
normal saline 
(2.8x10
2
) 
IV  B1 and mRS at 
day 180  
Similar in the two 
groups  
Autologous bone marrow-derived mesenchymal stem cells 
7. 25 : 5 patients 
1-year f/u 
Subacute Large MCA 
infarct 
Ex vivo culture 
expansion using 
fetal bovine serum 
(1x10
2
) 
IV  B1 improved at 
3 months  
None  
8. 36 : 16 patients 
5-year f/u
 
Subacute Large MCA 
infarct
 
Ex vivo
 
culture 
expansion using 
fetal bovine serum 
(1x10
2
)
 
IV
 
mRS 0-3, 
increased in 
MSC group
 
None
 
9. None : 12 
patients 1-year 
f/u
 
Subacute to chronic 
Variable
 
Ex vivo
 
culture 
expansion using 
autologous serum 
(1x10
2
)
 
IV
 
Limited study 
design
 
None
 
10.
 
6:6 patients 24-
week f/u
 
Chronic Ischemic or 
ICH
 
Ex vivo
 
culture 
expansion using 
serum-free media 
(5-6x10
2
)
 
IV
 
Modest increase 
in FM and mBI
 
None
 
Allogeneic neural stem/progenitor cells
 11.
 
None:5 patients 
Terminated 
early
 
Chronic MCA infarct 
affecting striatum
 
Ex vivo
 
culture 
expansion of NSCs 
obtained from 
primordial porcine 
striatum
 
IC
 
Limited study 
design
 
Seizure, 
aggravation of 
hemiplegia
 
12.
 
None:8 patients 
2-year f/u
 
Subacute
 
to chronic 
MCA/ACA infarct
 
Ex vivo
 
culture 
expansion of NSCs 
obtained from fetal 
brain
IC
 
Limited study 
design
 
Transient low-
grade fever only
 
Sr. No.
Table : Clinical Trials of Stem Cells in Patient with Stroke
ACA : anterior cerebral artery, B1 : Barthel index, FM : Meyer score, f/u : follow-up, IA : intra-arterial, IC : intra-cerebral, 
ICH : intra-cerebral hemorrhage, IV : intravenous, mBI : modiﬁed Barthel index, MCA : middle cerebral artery, 
mRS : modiﬁed Rankin Score, MSC : mesenchymal stem cell, N/A : not available, 
NIHSS : National Institutes of Health Stroke Scale, NSCs : neural stem/progenitor cells
techniques which could help generate patient 
and disease speciﬁc cells.
 Stem cells aid stroke recovery via 
mechanisms depending on the type of cells used. 
Transplanted ESCs, iPSCs, and NSCs can 
replace the missing brain cells in the infarcted 
area, while adult stem cells, such as MSCs and 
MNCs, provide trophic support to enhance self-
r e p a i r  s y s t e m s  s u c h  a s  e n d o g e n o u s 
neurogenesis.  Most preclinical studies of stem 
cell therapy for stroke have emphasized the need 
to enhance self-repair systems rather than to 
replace lost cells, regardless of the type of cells 
used.
Clinical Trials of Stem Cell Research in 
Stroke
 Among all types of cells, bone marrow- 
derived stem cells are used frequently in clinical 
trials with stroke (Table 1).  We have 
successfully transplanted bone marrow derived 
mononuclear and mesenchymal stem cells in 
chronic stroke (33-35). 
 The functional beneﬁts after neural 
transplantation are likely to be mediated by one 
o f  t h e  f o l l o w i n g  m e c h a n i s m s ,  i . e . , 
neurotransmitters released from the graft tissue 
act on the afferent deprived limb of the post 
synaptic receptors, release of the neurotrophic / 
growth factors, Brain-derived Neurotrophic 
Factor (BDNF), Glial-derived Neurotrophic 
Factor (GDNF), Nerve Growth Factor (NGF) 
acting as local pumps to support cell function 
and to  prevent  cascade of  apoptosis , 
regenerating neuronal population further 
prevents subsequent cell death, reestablishment 
of local interneuronal connections and synaptic 
connectivity between the host and graft, cell 
differentiation and integration, improvement of 
regional oxygen tension (36,37). 
 Our current stem cell trial investigates the 
paracrine mechanisms of mononuclear stem 
cells in chronic ischemic stroke, no serious 
adverse events were observed during the study. 
There was no statistically signiﬁcant clinical 
improvement between the groups (FM: 95% CI 
15.2-5.35, p=0.25; mBI: 95% CI 14.3-4.5, 
p=0.31). Vascular Endothelial Growth Factor 
(VEGF) and BDNF expression was found to be 
greater in one group compared to other (VEGF: 
442.1 vs. 400.3 pg/ml, p=0.67; BDNF: 21.3 vs. 
19.5 ng/ml) without any statistically signiﬁcant 
difference (38). 
Role of Noninvasive Brain Stimulation
 Noninvasive Brain Stimulation (NIBS) 
provides a valuable tool for interventional 
neurophysiology by modulating brain activity 
in a speciﬁc distributed, cortico-subcortical 
network (39, 40). Therapeutic utility of NIBS 
has been claimed in the literature for psychiatric 
disorders, such as depression, acutemania, 
bipolar disorders, schizophrenia, catatonia, 
post-traumatic stress disorder and neurologic 
diseases, such as stroke and parkinson's disease 
(41). The two most commonly used techniques 
for NIBS are Transcranial Magnetic Stimulation 
(TMS) and Transcranial Direct Current 
Stimulation (tDCS).  TMS is a neurostimulation 
and neuromodulation application, whereas 
tDCS is a purely neuromodulatory intervention, 
both having their effect on the parameters of 
stimulation (42,43). 
 Hsu et al conducted a meta-analysis on 
eighteen studies involving 392 patients on 
efﬁcacy of TMS post-stroke(44).  A signiﬁcant 
effect size of 0.55 was found for motor outcome 
(95% CI, 0.37-0.72) with subgroup analysis 
demonstrating more prominent effects on 
subcortical stroke (mean effect size~0.73; 95% 
CI, 0.44-1.02).  Only 4 patients of the 18 articles 
included in this analysis reported adverse effects 
from rTMS (44).  Low-frequency rTMS over 
the unaffected hemisphere may be more 
beneﬁcial than high-frequency rTMS. Recent 
data suggest that intermittent theta-burst 
stimulation over the affected hemisphere might 
be a useful intervention (45). 
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 Cicinelli et al (46,47) used focal TMS to 
map cortical representation via abductor digiti 
minimi (ADM) of the damaged hemisphere. It 
was observed that cortical excitability changed 
and there was an improvement in hand function. 
An ongoing research by our group which 
evaluates upregulation VEGF after acute 
ischemic stroke and its correlation with clinical 
recovery.  It also examines the effects of rTMS 
(1Hz) and correlates the expression of VEGF in 
stroke patients.  The results of this study are 
awaited. 
 Plautz (48) and Kleim et al (49) showed 
that cortical stimulation can reorganize 
movement representations to peri-infarct areas 
in primates and rats after ischemic lesions to 
their motor cortices.  The importance of 
contralesional activation during motor tasks 
involving the recovering hand or arm is not 
clear.  The effects seem to range from neutral or 
positive consequence such as adaptive 
neuroplastic process to negative maladaption 
that may interfere with recovery. 
 In Transcranial Direct Current Stimulation 
(tDCS), low-amplitude direct currents are 
applied via scalp electrodes and penetrate the 
skull to enter the brain. Although the currents 
applied do not usually elicit action potentials, 
they modify the transmembrane neuronal 
potential and thus inﬂuence the level of 
excitability modulating the ﬁring rate of 
individual neurons  (50,51). 
 Lindenberg et al (52) conducted a study on 
twenty chronic stroke patients which were 
randomly assigned to receive 5 consecutive 
sessions of either a) bihemispheric tDCS 
(anodal tDCS to upregulate excitability of 
ipsilesional motor cortex and cathodal tDCS to 
down-regulate excitability of contralesional 
motor cortex) with physiotherapy or b) sham 
st imulat ion with physiotherapy.   The 
improvement  o f  moto r  func t ion  was 
signiﬁcantly greater in the real stimulation 
group (20.7% in Fugl-Meyer and 19.1% in Wolf 
Motor Function Test scores) when compared to 
the sham group (3.2% in Fugl-Meyer and 6.0% 
in Wolf Motor Function Test scores) lasting for 1 
week. 
 Anodal  s t imulat ion increases the 
spontaneous ﬁring rate and the excitability of 
cortical neurons by depolarizing the membranes 
where as cathodal stimulation leads to neuronal 
hyperpolarization resulting in a decrease of the 
neuronal ﬁring rate and excitability.  It was 
found that  anodal (facil i tatory) tDCS 
stimulation of the ipsilesional hemisphere was 
associated with greater behavioral gains (better 
response time) as compared to cathodal 
(inhibitory) tDCS of the contralesional 
hemisphere and was associated with increased 
activation within ipsilesional M1 and PMd (53, 
54).  This pattern of activity was ﬁrst shown in 
animals receiving stimulation via epidural or 
intracerebral electrodes.  Therefore, facilitatory 
stimulation of the ipsilesional hemisphere may 
lead to gains in motor function by increasing 
activation within ipsilesional motor areas (55).
 Our group, in a randomized placebo 
controlled trial is evaluating the efﬁcacy of 
tDCS and ﬂuoxetine on chronic stroke on 
balance and gait. The patients are randomized to 
four groups; real and sham tDCS and ﬂuoxetine 
groups with dual task exercise regime 
administered to all patients. This is an ongoing 
study with results awaited.
Role of Mirror Therapy/ Virtual Reality
 Mirror therapy was ﬁrst described by 
Ramachandran in 1996 reporting its efﬁcacy on 
pain reduction in armamputees and later was 
claimed to alleviate hemiparesis after stroke. A 
pilot study conﬁrmed the positive effects of 
mirror therapy on facilitation in upper limb 
hemiparesis after stroke (56). Mirror therapy is 
deﬁned as an intervention that uses a mirror to 
create a reﬂection of the non-paretic upper or 
lower limb, thus giving the patient visual 
feedback of normal movement of the paretic 
limb. In a systematic review, fourteen studies 
were included with 9-121 participants. It was 
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found that mirror therapy had a signiﬁcant effect 
on motor function (SMD 0.61;95%; CI~0.22 
2
to1;p=0.002; I =75%) (57). We also conducted a 
study with mirror therapy in chronic stroke 
patients using a web cam that captured the 
normal hand which was seen as affected in the 
laptop screen. Bilateral hand training were 
administered to patients and it was observed that 
MT improved hand function in FM and mBI 
scores along with an increased in laterality index 
(LI) in ipsilesional BA 4 and 6 (58).  
Role of Constraint Induced Movement 
Therapy (CIMT) and Electrical Stimulation
 CIMT  has been investigated in 51 RCTs 
including 1784 patients with adult stroke, only 
15 trials included patients within the ﬁrst three 
months post-stroke. From systematic review 
(59), it is evident that original and modiﬁed 
versions of CIMT have a robust, clinically 
meaningful impact on patient's outcomes for 
arm-hand activities, self-reported hand use in 
daily life and basic ADL, making it one of the 
most effective interventions for the paretic limb 
post-stroke. It has also been reported that 
patients with poorer baseline behavior showed 
largest improvement on the wolf motor function 
test with increases in activation within the 
ipsilesional sensorimotor cortex during ﬁnger 
ﬂexion/extension (60). Increased movement of 
the paretic upper extremity and decreased 
reliance on the non-paretic upper extremity are 
core features of CIMT (61).
 Neuromuscular Electrical Stimulation 
(NMES) induces depolarization of peripheral 
neurons and subsequently elicits muscle 
contractions (62). It causes physiological 
changes after the stimulation, facilitating plastic 
changes during recovery and leading to 
improvement of voluntary functions. Functional 
Electrical Stimulation (FES) is one of the 
methods that uses electrical currents in 
stimulating the nerves connected to the 
paralyzed muscles in precise sequence and 
magnitude so that the outcome resembles 
functional tasks. FES aims to generate 
movements or functions, which mimic normal 
voluntary movements and therefore restore the 
functions (63). FES has some speciﬁc 
characteristics that makes it distinct from other 
forms of electrical stimulation. The frequency 
range of FES falls between 10 and 50 Hz and it 
directly stimulates the nerves or their motor 
points, not the muscle ﬁbers. In 2002, Ada and 
Foongchomcheay (64) conducted a meta-
analysis on the effect of electrical stimulation on 
shoulder outcomes after stroke. They showed 
that FES was superior to conventional therapy 
alone in the treatment of shoulder subluxation 
and arm motor function but was not effective in 
the treatment of pain early after stroke. 
Robotic Technology in Stroke
 The role of robotics in post-stroke 
rehabilitation has been investigated intensively. 
The robot-assisted rehabilitation of the upper 
limb in the acute and subacute post-stroke phase 
is  successfully used an alternative to 
conventional mobilization, resulting in effective 
conventional therapy. Masiero et al (65) 
hypothesized that an optimal robotic training 
protocol for acute and subacute stroke patients 
should be divided in two stages: initial 
additional robotic training (ﬁrst stage) followed 
by substitution of part of the conventional 
therapy with the robotic exercise (second stage) 
(66). The introduction of robotic systems into 
clinical practice is useful in promoting a cost-
effective use of human resources and the 
standardization of rehabilitation treatments. 
Hornby et al (67) performed a randomized 
controlled study comparing the effects of robot-
assisted gait training that uses exoskeleton 
devices and manual facilitation that uses an 
assist on gait function in patients with chronic 
stroke. Another investigator also studied the 
usefulness of robot-assisted therapy in patients 
with subacute stroke in a multicenter 
randomized trial. They concluded that the 
diversity of conventional gait training 
interventions appeared to be more effective than 
robot-assisted gait training for improving 
walking ability (68). A study by Lo et al 
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recruited 127 chronic stroke patients reported 
that robot-assisted therapy and conventional 
therapy produced s imilar  amounts  of 
improvement after 12 weeks of treatment and 
after 36 weeks of therapy, the robot-assisted 
therapy achieved greater motor improvement 
than did conventional therapy (69).
Pharmacological Agents
 Pharmacological therapy post-stroke may 
seem merely a chimera, translation of drugs 
from the laboratory to the clinic should be 
performed with caution, failure of which from 
the bench to bed side transition will be 
devastating. For example erythropoietin (EPO) 
was demonstrated in multiple clinical studies to 
provide therapeutic beneﬁt. Phase II clinical 
trial was unsuccessful and had to be terminated 
because of high mortality and adverse events. 
Nitric Oxide (NO)
 NO is an “endothelial-derived relaxing 
factor” which is involved in maintaining 
endothelial cell integrity, as well as participating 
in hemodynamic homeostasis (70). NO is also a 
potent activator of soluble guanylatecyclase, the 
enzyme that converts GTP to cGMP, the 
delivery of NO donor increases cGMP levels 
within both ischemic and non-ischemic rat 
brains, suggesting a permissive role for NO in 
neurogenesis. The increased expression of 
neuronal NO synthase within the Subvenricular 
Zone (SVZ) during embryogenesis suggests an 
important role for the NO pathway in 
neurogenesis (71,72). In addition to enhancing 
cGMP levels by augmenting NO availability, 
cGMP levels may also be increased by 
i n h i b i t i n g  i t s  m e t a b o l i s m  b y  t h e 
Phosphodiesterase-5 (PDE5) enzyme (73). 
Animals treated with sildenaﬁl, a PDE5 
inhibitor post-stroke achieved signiﬁcant and 
substantial increase in neurological functional 
recovery (74). It demonstrated improved 
cerebral blood ﬂow (CBF), neurogenesis and 
synaptogenesis following experimental stroke, 
even when therapy was delayed for up to 1 
week. 
Gamma Amino Butyric Acid (GABA)
 Recovery after stroke involves remapping 
of the neuronal circuitry in the regions adjacent 
to the site of injury or the peri infarct zone (75).  
A pharmacological approach to re-establish 
functional neuronal connections that are lost 
during stroke could enhance current physical 
rehabilitation therapies.  It is also proven that 
inhibiting GABAergic signaling pathways after 
stroke can improve locomotor function, 
suggesting a therapeutic approach that is less 
time sensitive than acute reperfusion therapies. 
Selective Serotonin Reuptake Inhibitors 
(SSRIs)
 Animal studies suggest that SSRIs may be 
involved in neurogenesis and activation of 
cortical motor areas modulating neuronal 
plasticity (76).  These drugs are essential in 
m a i n t a i n i n g  s l e e p  r h y t h m ,  a n d 
neurotransmitters levels within the brain and 
have been tried in stroke rehabilitation trials.  A 
single dose of citalopram can normalize the 
balance in cortical excitability, as measured by 
transmagnetic stimulation.  Patients more than 6 
months after stroke, in a single dose cross over 
exper iment  wi th  c i t a lopram,  showed 
improvement in hand dexterity as measured by 
the nine-hole peg test (77).  A single dose of 
ﬂuoxetine given 2-3 weeks after stroke showed 
improved motor skills on the none-hole peg test, 
and increased activation of the affected side on 
functional resonance imaging.  A meta-analysis 
of randomized controlled trials on stroke 
patients treated with SSRI compared to usual 
care or sham; identiﬁed 52 trials for analysis and 
it was found that these drugs are associated with 
an improvement in functionality, neurological 
impairment, disability and depression (78). 
Minocycline 
 Minocycline is the second generation 
tetracycline derivative known to have anti-
inﬂammatory effects independent of its 
antimicrobial action (79).  Studies have shown 
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that minocycline prevents microglial activation, 
and has notable beneﬁcial effects in animal 
models of global and transient focal cerebral 
ischemia.  The proposed mechanisms of 
minocycline include anti-inﬂammatory effects, 
reduction of microglial activation, MMP 
reduction, NO production and inhibition of 
apoptotic cell death (80).  In a randomized 
single blinded study, we studied the effects of 
oral minocycline (200 mg/day for 5 days) post-
stroke versus placebo.  Of 50 patients included 
in the trial, patients who received minocycline 
had better recovery in stroke outcome as noted 
on NIHSS, mBI and mRS scores (81).
Cerebrolysin
 This is a peptide-based drug with potential 
to be used as a restorative agent.  Multiple 
laboratories have demonstrated the safety and 
efﬁcacy of this drug in the treatment of 
experimental stroke.  It has been known to 
induce neurogenesis and angiogenesis in animal 
models of stroke and concomitantly enhances 
brain plasticity and recovery from stroke.
Niaspan
 It is an extended release formulation of 
Niacin, proposed to be effective in reducing 
neurological deﬁcits post-stroke by promoting 
axonal  remodel ing ,  angiogenes is  and 
arteriogenesis (82).  Niacin-induced increase in 
synaptic plasticity and axon growth may be 
mediated by the  up-regula t ion in  the 
BDNF–TrkB axis (Cui et al, 2010).  In the 
mature nervous system, BDNF/TrkB plays an 
important role in regulating neuronal migration, 
differentiation, synaptic remodeling, and 
survival.  Niacin treatment after stroke 
signiﬁcantly increases BDNF/TrkB expression 
both in the ischemic brain and in primary cortical 
neuron (PCN) cultures (82).   It has also been 
proven that combination of Niaspan with 
Simvastatin helped improve overall functional 
outcome signiﬁcantly and decreased axonal 
damage and density (83).
Neuroimaging Provides Insight into 
Neuroplasticity
 A wide number of neuroimaging methods 
exist for evaluating the state of Central Nervous 
System (CNS) function and structure after 
stroke. Brain function can be measured using 
functional Magnetic Resonance Imaging 
(fMRI), Positron Emission Tomography (PET), 
e l e c t r o e n c e p h a l o g r a p h y  ( E E G ) , 
magnetoencephalography (MEG), Transcranial 
Magnetic Stimulation (TMS) and near infrared 
spectroscopy (84).  These techniques measure 
the volume of regional brain activation, the 
magnitude of activation and the balance of 
activation across hemispheres, often reported as 
a laterality index, during a task or at rest. Each 
technique has its merits and limits, MRI 
involves no isotopes and can also measure 
Cerebral Blood Flow (CBF) and angiography; 
PET can be used to measure CBF, metabolism, 
neurochemistry, and receptor kinetics; and TMS 
and MEG have temporal resolution at the 
millisecond level.  Diffusion Tensor Imaging 
(DTI) is an MRI method for examining white 
matter integrity via measures such as Fractional 
Anisotropy (FA) enabling delineation of the 
anatomical connectivity of white-matter 
pathways (85). 
 An increasing number of studies have 
examined the mechanisms of spontaneous 
recovery after stroke. Studies have elucidated 
many of the cellular and molecular events, both 
near and remote from the lesion, that underlie 
spontaneous post-stroke improvements.  These 
results are concordant with many of the ﬁndings 
from noninvasive neuroimaging methods in 
human subjects mentioned above .
Conclusion
 Neurorestoration is a concept that has been 
proven emphatically in several experimental 
models and clinical studies of stroke. 
Elucidating the underlying mechanisms of cell-
based, pharmacological and rehabilitative 
therapies is of primary interest and crucial for 
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translation of treatments to clinical use. The 
knowledge must provide an impetus for the 
development of superior, advanced & cost- 
effective neurorestorative interventions that 
will enhance stroke recovery.
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